The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L. M., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 136
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M. E., Boyle, G. E., Liu, C., Götz, J., Buisson, A., & Lesné, S. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 118
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Items 501–600 of 867
Looking at Alzheimer’s Disease Pathogenesis from the Nuclear Side
D’Andrea, L., Stringhi, R., Luca, M. D., & Marcello, E. E. (2021) · Biomolecules · doi:10.3390/biom11091261 · Cited by 10
Sun, D., Chen, C., Moschke, K., Huang, J., & Fang, W. (2019) · Molecules · doi:10.3390/molecules25010102 · Cited by 9
Indig, R. Y., & Landau, M. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102318 · Cited by 5
Sánchez-Puebla, L., López‐Cuenca, I., Salobrar‐García, E., González-Jiménez, M., Vázquez, A. A., Matamoros, J. A., Ramirez, A. I., Fernández‐Albarral, J. A., Elvira‐Hurtado, L., Saido, T. C., et al. (2024) · Biomolecules · doi:10.3390/biom14070828 · Cited by 8
Schützmann, M. P., & Hoyer, W. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169048 · Cited by 9
Neuroadaptation in neurodegenerative diseases: compensatory mechanisms and therapeutic approaches
Kopalli, S. R., Behl, T., Baldaniya, L. H., Ballal, S., Joshi, K. K., Arya, R., Chaturvedi, B., Chauhan, A. S., Verma, R. K., Patel, M., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111375 · Cited by 8
Panda, H. S., Dhokne, M. D., Thakur, S., Singh, N. K., Datusalia, A. K., & Panda, J. J. (2025) · Small · doi:10.1002/smll.202411701 · Cited by 7
Recent advances in nanomaterial-based biosensors for Alzheimer's disease diagnosis: a review
Liu, Q., Xu, X., & Zheng, T. (2025) · Chemical Communications · doi:10.1039/d5cc02469b · Cited by 10
Zhao, J., Cheng, S., Wang, X., Yu, R., Du, B., Tong, J., Liu, Y., Qing, T., & Liu, X. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.166632 · Cited by 8
Wijesinghe, P., Hosseini, A., Campbell, M., Tejpal, S., Haynes, J. R., Xi, J., Mackenzie, I. R., Hirsch‐Reinshagen, V., Hsiung, G. R., Spiller, B. W., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70592 · Cited by 8
Hofmann, C., Sander, A., Wang, X. X., Buerge, M., Jungwirth, B., Borgstedt, L., Kreuzer, M., Kopp, C., Schorpp, K., Hadian, K., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201185 · Cited by 8
Puławski, W., & Dzwolak, W. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c00699 · Cited by 7
Viles, J. H. (2023) · Angewandte Chemie · doi:10.1002/ange.202215785 · Cited by 8
M13 phage grafted with peptide motifs as a tool to detect amyloid-β oligomers in brain tissue
Martins, I. M., Lima, A., de Graaff, W., Cristóvão, J. S., Brosens, N., Aronica, E., Kluskens, L., Gomes, C. M., Azeredo, J., & Kessels, H. W. H. G. (2024) · Communications Biology · doi:10.1038/s42003-024-05806-5 · Cited by 7
Gonçalves, P. B., Cordeiro, Y., & Sodero, A. C. R. (2024) · RSC Advances · doi:10.1039/d4ra03343d · Cited by 8
Cline, E. N., Antwi‐Berko, D., Sundell, K. L., Johnson, E. A., Hyland, M., Zhang, H., Vanderstichele, H., Kaplow, J. M., Dean, R. A., Stoops, E., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100082 · Cited by 9
Self-citationWang, J., Chen, L., Wang, Z., Chen, X., Zhang, S., Ding, D., Zhou, Y., Rager-Aguiar, R., Lin, G., Zhang, H. J., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03592-6 · Cited by 9
Challenges in understanding the structure/activity relationship of Aβ oligomers
Pilkington, A. W., & Legleiter, J. A. (2019) · AIMS Biophysics · doi:10.3934/biophy.2019.1.1 · Cited by 10
Murakami, K., Horii, S., Hanaki, M., & Irie, K. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00489 · Cited by 7
Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
Frölich, L., & Hausner, L. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01222-w · Cited by 13
Aβ 42 oligomers can seed the fibrillization of Aβ 40 peptides
Wu, Y., Huang, S., Wu, M., Tu, L., Lee, M., & Chan, J. C. C. (2022) · Journal of the Chinese Chemical Society · doi:10.1002/jccs.202200136 · Cited by 8
Wang, P., Zhang, S., Hu, C., Ren, L., & Bi, J. (2023) · Molecular Biology Reports · doi:10.1007/s11033-022-08213-3 · Cited by 9
β-Hairpin Alignment Alters Oligomer Formation in Aβ-Derived Peptides
Ruttenberg, S. M., Kreutzer, A. G., Truex, N. L., & Nowick, J. S. (2024) · Biochemistry · doi:10.1021/acs.biochem.3c00526 · Cited by 7
Kaar, A., Weir, M. P., & Rae, M. G. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137664 · Cited by 10
Hark, T. J., & Savas, J. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15298 · Cited by 8
Lee, A.-H., Hong, S.-C., Park, I., Yoon, S., Kim, Y. S., Kim, J., & Yang, S. (2021) · Applied Sciences · doi:10.3390/app11135878 · Cited by 9
Yuen, S. C., Lee, S. M., & Leung, S.-W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215349 · Cited by 7
Scan-Find-Scan-Model: Discrete Site-Targeted Suppressor Design Strategy for Amyloid-β
Bhagavatula, H., Sarkar, A., Santra, B., & Das, A. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00272 · Cited by 7
Stable Cavitation Interferes with Aβ16–22 Oligomerization
Man, V. H., He, X., & Wang, J. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00764 · Cited by 7
Siniscalco, D., Francius, G., Tarek, M., Bali, S. K., Laprévôte, O., Malaplate, C., Oster, T., Gregory, L., & Quilès, F. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c22196 · Cited by 8
Stögmann, E., & Schmidt, R. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02466-7 · Cited by 6
“According to the amyloid cascade hypothesis and its extensions [2], amyloid pro-teinopathy represents the initial central event in the pathophysiology that interacts with tau proteinopathy [3] and then triggers a multitude of further molecular cascades leading to synaptic dysfunction and…”
Impact of Amidation on Aβ 25–35 Aggregation
Etaka, J. C. E., Lü, Y., Kang, W., Salsbury, F. R., & Derreumaux, P. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c07692 · Cited by 6
Wang, Z., Ding, D., Wang, J., Ling, C., Dong, Q., Khamrai, M., Zhou, Y., Ishii, A., Sakata, K., Li, W., et al. (2025) · Cells · doi:10.3390/cells14110843 · Cited by 7
PANoptosis: Potential Therapeutic Prospects in Alzheimer's Disease
Guo, Z., & Wan, Y. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70231 · Cited by 9
Shim, G., Hall, R., Zhang, Z., Shokry, I. M., To, A., Cruz, L., Adam, M. C., Prentice, H. M., Wu, J., Su, H., et al. (2025) · Cells · doi:10.3390/cells14221754 · Cited by 7
Relationship between efficacy and preferential targeting of soluble Aβ aggregates
Kaplan, J. M., Gibbs, E., Coutts, J. A., Zhao, B., Mackenzie, I. R., Plotkin, S. S., & Cashman, N. R. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70184 · Cited by 10
Zhang, B.-B., Yu, X.-Y., & Zhang, X. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08893-w · Cited by 5
Toxic mechanisms of amyloid oligomers and therapeutic strategies
Ivanova, M. I., Rosa, C. L., & Ramamoorthy, A. (2026) · Protein Science · doi:10.1002/pro.70519 · Cited by 6
Pinheiro, N. R., Carneiro, C. F. D., Cancelliero, G. S., Nogueira, G. O., de Almeida, G. M., Fernandes, N., Wasilewska‐Sampaio, A. P., Martins, S. M., Filho, A. F. D. S., Amaral, O. B., et al. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70523 · Cited by 8
Recombinant Antibody Fragments for Neurological Disorders: An Update
Manoutcharian, K., & Gevorkian, G. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230830142554 · Cited by 7
Kandi, S., Cline, E. N., Rivera, B. M., Viola, K. L., Zhu, J., Condello, C., LeDuc, R. D., Klein, W. L., Kelleher, N. L., & Patrie, S. M. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00353 · Cited by 6
Self-citationCoelho, R., Benedictis, C. A. D., Sauer, A. K., Figueira, A. J., Faustino, H., Grabrucker, A. M., & Gomes, C. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031787 · Cited by 6
Amyloid-β Pathology Is the Common Nominator Proteinopathy of the Primate Brain Aging
Ferrer, I. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240389 · Cited by 7
Mitroshina, Е. V., Kalinina, E. P., Kalyakulina, A., Teplyakova, A. V., & Vedunova, M. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212237 · Cited by 9
Coleman, P. D., Delvaux, E., Kordower, J. H., Boehringer, A. V., & Huseby, C. J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14555 · Cited by 8
Yamasaki, T., Aso, T., Kaseda, Y., Mimori, Y., Doi, H., Matsuoka, N., Takamiya, N., Torii, T., Takahashi, T., Ohshita, T., et al. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134402 · Cited by 7
Pepperberg, D. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190476 · Cited by 7
Nah, E., Cho, S., Park, H., Noh, D., Hwang, I., & Cho, H. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23933 · Cited by 6
Fas Apoptosis Inhibitory Molecule Blocks and Dissolves Pathological Amyloid-β Species
Kaku, H., Ludlow, A. V., Gutknecht, M. F., & Rothstein, T. L. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.750578 · Cited by 6
Wu, J., Blum, T. B., Farrell, D. P., DiMaio, F., Abrahams, J. P., & Luo, J. (2021) · Angewandte Chemie · doi:10.1002/ange.202104497 · Cited by 6
Protofibril–Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation
Hasecke, F., Niyangoda, C., Borjas, G. J., Pan, J., Matthews, G., Muschol, M., & Hoyer, W. (2020) · Angewandte Chemie · doi:10.1002/ange.202010098 · Cited by 6
Russ, H., Mazzanti, M., Parsons, C. G., Riemann, K., Gebauer, A., & Rammes, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105794 · Cited by 7
Hilt, S., Liu, R., Maezawa, I., Rojalin, T., Aung, H. H., Budamagunta, M. S., Slez, R. R., Gong, Q., Carney, R. P., & Voss, J. C. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.896386 · Cited by 8
Curcumin tautomerization in the mechanism of pentameric amyloid- β42 oligomers disassembly
Matsui, A., Bellier, J., Hayashi, D., Ishibe, T., Nakamura, Y., Taguchi, H., Naruse, N., & Mera, Y. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.076 · Cited by 7
Shin, H. J., Kim, K. E., Jeong, E. A., An, H. S., Lee, S. J., Lee, J., & Roh, G. S. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.026 · Cited by 7
Yu, Z., Moshood, Y., Woźniak, M., Patel, S., Terpstra, K., Llano, D. A., Dobrucki, L. W., & Mirica, L. M. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202302408 · Cited by 7
Cerebrospinal fluid solute transport associated with sensorimotor brain activity in rodents
Kim, E., Reet, J. V., & Yoo, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-43920-2 · Cited by 6
Split aptazyme-based signal amplification for AβO analysis
Duan, C., Yao, Y., Cheng, W., Chen, Y., Jiao, J., & Xiang, Y. (2023) · Talanta · doi:10.1016/j.talanta.2023.125351 · Cited by 6
Zhao, Q., Ma, L., Chen, S., Huang, L., She, G., Sun, Y., Shi, W., & Mu, L. (2024) · Talanta · doi:10.1016/j.talanta.2024.125716 · Cited by 6
Puzzo, D., & Conti, F. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.684977 · Cited by 6
Mrđenović, D., Lipkowski, J., & Pięta, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1843-1_18 · Cited by 6
Guaglianone, G., Torrado, B., Lin, Y.-F., Watkins, M. C., Wysocki, V. H., Gratton, E., & Nowick, J. S. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00313 · Cited by 6
Servizi, S., Corrigan, R. R., & Casadesús, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200318151146 · Cited by 6
Aβ oligomer induced cognitive impairment and evaluation of ACU193‐MNS‐based MRI in rabbit
Rozema, N. B., Procissi, D., Bertolino, N., Viola, K. L., Nandwana, V., Abdul, N., Pribus, S. J., Dravid, V. P., Klein, W. L., Disterhoft, J. F., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12087 · Cited by 8
Self-citationPittman, J. M., Srivastava, A. K., Boughter, C. T., Venkata, B. S., Zerweck, J., Moore, P. C., Smok, I., Tonelli, M., Sachleben, J. R., & Meredith, S. C. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00147 · Cited by 6
Sakata, T., Shiratori, R., & Kato, M. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04339 · Cited by 6
Cellular prion protein offers neuroprotection in astrocytes submitted to amyloid β oligomer toxicity
Marques, C. M. S., Gomes, R. N., Pedron, T., Batista, B. L., & Cerchiaro, G. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04631-w · Cited by 6
Krasinski, C. A., Zheng, Q., Ivancic, V. A., Spratt, D. E., & Lazo, N. D. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00305 · Cited by 7
Ultrasensitive Assays Detect Different Conformations of Plasma β Amyloids
Li, C.-Y., Fan, L., Lin, C., Hu, C., & Chiu, M. (2025) · ACS Omega · doi:10.1021/acsomega.4c10879 · Cited by 7
Sharma, A., Maity, S., Gupta, S., Ali, A., Ali, A., & Asati, V. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2025.101804 · Cited by 6
Cascade autohydrolysis of Alzheimer's Aβ peptides
Wolfram, M., Tiwari, M. K., Hassenkam, T., Li, M., Bjerrum, M. J., & Meldal, M. (2023) · Chemical Science · doi:10.1039/d2sc06668h · Cited by 6
Wang, W.-H., Kao, Y.-C., Hsieh, C.-H., Tsai, S.-Y., Cheung, C. H. Y., Huang, H., & Juan, H. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00566 · Cited by 5
Maity, B., Kameyama, S., Tian, J., Pham, T. T., Abe, S., Chatani, E., Murata, K., & Ueno, T. (2024) · Biomaterials Science · doi:10.1039/d4bm00173g · Cited by 5
Therapeutic effects of a novel synthetic α-secretase
Kim, S. B., Mun, B.-R., Kim, S. Y., Elangovan, M., Park, E. J., Choi, W., & Park, W. J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1383905 · Cited by 5
Early involvement of D-serine in β-amyloid-dependent pathophysiology
Billard, J., Ploux, E., Largillière, S., Corvaisier, S., Gorisse-Hussonnois, L., Radzishevsky, I. S., Wolosker, H., & Fréret, T. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05691-z · Cited by 5
Amabebe, E., Huang, Z., Jash, S., Krishnan, B., Cheng, S., Nakashima, A., Li, Y., Li, Z., Wang, R., Menon, R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines13010029 · Cited by 7
The Brain Toxin Cleansing of Sleep Achieved During Wakefulness
Arendash, G. W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030926 · Cited by 8
Gu, S., & Ran, C. (2025) · iRadiology · doi:10.1002/ird3.70002 · Cited by 5
The Potential Role of Neurogranin in Alzheimer’s Disease
Zhou, X., Jing, X.-J., & Zhang, H. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin25368 · Cited by 5
The relationship between postoperative delirium and plasma amyloid beta oligomer
Yang, Y., Jung, K. J., & Kwak, Y. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-97577-0 · Cited by 8
Fu, Y., Zhang, J., Yang, C., Wang, Y., Yang, Y., Qiu, P., Xie, W., Zhang, S., & Lǚ, T. (2025) · International Journal of Toxicology · doi:10.1177/10915818251338235 · Cited by 6
Li, H., Zhao, Z., Fassini, A., Lee, H. K., Green, R. J., & Gomperts, S. N. (2025) · Scientific Reports · doi:10.1038/s41598-025-05653-2 · Cited by 9
Redox reactivities of membrane-bound amyloid-β-Cu complexes and their targeting by metallothionein-3
Perez-Medina, L., & Meloni, G. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.047 · Cited by 6
Ayon, N. J. (2025) · AppliedChem · doi:10.3390/appliedchem5040035 · Cited by 7
Rovetta, A., Carosella, L., Arrigoni, F., Vertemara, J., GIOIA, L. D., Zampella, G., & Bertini, L. (2023) · Inorganics · doi:10.3390/inorganics11060227 · Cited by 7
Yi, J. H., Cho, E., Lee, S., Kwon, K. J., Lee, S., Lee, J., Lee, C., Shin, C. Y., Kim, D. H., & Shim, S. H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115792 · Cited by 8
Visualization of Amyloid Oligomers in the Brain of Patients with Alzheimer’s Disease
Tooyama, I., Kato, T., Taguchi, H., Kageyama, Y., Irie, K., Hirahara, Y., & Yanagisawa, D. (2023) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.23-00058 · Cited by 5
Shim, Y. (2023) · Current Alzheimer Research · doi:10.2174/0115672050284054240119101834 · Cited by 6
Jamerlan, A., Shim, K. H., Sharma, N., & An, S. S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031199 · Cited by 6
Bioactive compound nanoparticles for Alzheimer's disease
Kshirsagar, N., Patil, A., & Suryawanshi, M. V. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01801-2 · Cited by 6
Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies
Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 8
Schubert, E. A., Kayser, V., & Wheate, N. (2019) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-018-00879-2 · Cited by 5
Wang, K., Na, L., & Duan, M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200916123000 · Cited by 6
Research Progress of Alzheimer’s Disease Therapeutic Drugs: Based on Renin-Angiotensin System Axis
Li, X., Xuan, W.-T., Chen, D., Gao, H., Wang, G., Guo, Q., Wang, Y., Song, H., & Cai, B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200770 · Cited by 5
Chien, H.-M., He, R., Lee, C.-C., Huang, Y., Hung, I.-J., Hou, K.-T., Hsiao, J., Lu, P.-C., Agnihotri, D., Hwang, E., et al. (2021) · Communications Chemistry · doi:10.1038/s42004-021-00547-6 · Cited by 5
Lyubchenko, Y. L. (2020) · Alzheimer s Research & Therapy Open Access · doi:10.23880/artoa-16000114 · Cited by 7
Supramolecular Bait to Trigger Non‐Equilibrium Co‐Assembly and Clearance of Aβ42
Wu, T., Lai, R., Yao, C., Juang, J., & Lin, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202013754 · Cited by 5
The Ups and Downs of Amyloid in Alzheimer's
Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5
The Era of Neurodegenerative Metastasis
Narayan, M. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00371 · Cited by 5
Bale, L. K., West, S. A., Gades, N. M., Baker, D. J., & Conover, C. A. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114976 · Cited by 4
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.